Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey
Listen now
Description
This episode features Sue-Ling Chang, (CHU de Québec-Université Laval Research Center, Oncology Division, Québec City, QC, Canada)   What is already known about the topic? There is a growing interest in psilocybin-assisted therapy worldwide, particularly to treat existential distress at the end of life.   What this paper adds? In this study, we show that the social acceptability of psilocybin-assisted therapy to treat existential distress at the end of life is high in Canada and identify factors associated with favourable attitudes of the population towards it.   Implications for practice, theory, or policy Our findings may help mobilise resources to address barriers and challenges for implementing psilocybin-assisted therapy within palliative medicine and society. This could also have implications for policies regarding medical assistance in dying.  Full paper available from:     https://journals.sagepub.com/doi/full/10.1177/02692163231222430  If you would like to record a podcast about your published (or accepted) Palliative Medicine paper, please contact Dr Amara Nwosu:  [email protected]
More Episodes
This episode features Dr Fiona Kenney and Koby Anderson, (Ottawa Hospital Research Institute, Ottawa, ON, Canada Bruyère Research Institute, Ottawa, ON, Canada)   What is already known about the topic? Previous research demonstrates a high prevalence of severe grief symptoms up to a year...
Published 03/13/24
This episode features Dr Carlos Seiça Cardoso (Faculty of Medicine, University of Coimbra, Coimbra, Portugal CINTESIS@RISE, MEDCIDS, Faculty of Medicine of the University of Porto, Porto, Portugal)  What is already known about the topic? The burden of chronic, progressive, incurable and...
Published 02/21/24